Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-56dfb582fe4596bebf9f4c8e3931299d",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-56dfb582fe4596bebf9f4c8e3931299d",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-56dfb582fe4596bebf9f4c8e3931299d",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-56dfb582fe4596bebf9f4c8e3931299d\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-56dfb582fe4596bebf9f4c8e3931299d</b></p><a name=\"composition-en-56dfb582fe4596bebf9f4c8e3931299d\"> </a><a name=\"hccomposition-en-56dfb582fe4596bebf9f4c8e3931299d\"> </a><a name=\"composition-en-56dfb582fe4596bebf9f4c8e3931299d-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/402/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - increlex</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/07/402/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp56dfb582fe4596bebf9f4c8e3931299d"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - increlex",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What INCRELEX is and what it is used for</li><li>What you need to know before you use INCRELEX</li><li>How to use INCRELEX</li><li>Possible side effects</li><li>How to store INCRELEX</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What increlex is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What increlex is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul><li></li></ul><h2 id=\"increlex-is-a-liquid-that-contains-mecasermin-which-is-a-man-made-insulin-like-growth-factor-1-igf-1-which-is-similar-to-the-igf-1-made-by-your-body\">INCRELEX is a liquid that contains mecasermin which is a man-made insulin-like growth factor-1 (IGF-1), which is similar to the IGF-1 made by your body.</h2><p>It is used to treat children and adolescents from 2 to 18 years old who are very short for their age because their bodies do not make enough IGF-1. This condition is called primary IGF-1 deficiency.</p></div>"
}
},
{
"title" : "2. What you need to know before you take increlex",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take increlex"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"do-not-use-increlex\">Do not use INCRELEX</h2><h2 id=\"if-you-currently-have-any-tumour-or-growth-either-cancerous-or-non-cancerous\">If you currently have any tumour or growth, either cancerous or non-cancerous</h2><h2 id=\"if-you-have-had-cancer-in-the-past\">if you have had cancer in the past</h2><h2 id=\"if-you-have-any-conditions-which-may-increase-the-risk-of-cancer\">if you have any conditions which may increase the risk of cancer</h2><h2 id=\"if-you-are-allergic-to-mecasermin-or-any-of-the-other-ingredients-of-this-medicine-listed-in-section-6\">if you are allergic to mecasermin or any of the other ingredients of this medicine (listed in section 6).</h2><h2 id=\"in-premature-babies-or-neonates-because-it-contains-benzyl-alcohol-warnings-and-precautions-there-is-an-increased-risk-of-tumours-and-growths-both-cancerous-and-non-cancerous-in-children-and-adolescents-treated-with-increlex-if-any-new-growth-skin-lesion-or-any-unexpected-symptom-occurs-during-treatment-or-after-treatment-see-your-doctor-immediately-since-mecasermin-may-play-a-role-in-cancer-development-talk-to-your-doctor-or-pharmacist-before-using-increlex\">in premature babies or neonates because it contains benzyl alcohol. Warnings and precautions There is an increased risk of tumours and growths (both cancerous and non-cancerous) in children and adolescents treated with INCRELEX. If any new growth, skin lesion or any unexpected symptom occurs during treatment or after treatment, see your doctor immediately since mecasermin may play a role in cancer development.<br/>Talk to your doctor or pharmacist before using INCRELEX</h2><h2 id=\"if-you-have-a-curved-spine-scoliosis-you-should-be-monitored-for-progression-of-scoliosis\">if you have a curved spine (scoliosis). You should be monitored for progression of scoliosis.</h2><h2 id=\"if-you-develop-a-limp-or-hip-or-knee-pain\">if you develop a limp or hip or knee pain</h2><p>if you have enlarged tonsils (tonsillar hypertrophy). You should have examinations periodically.</p><ul><li>if you have symptoms of increased pressure in the brain (intracranial hypertension), such as visual changes, headache, nausea and/or vomiting, contact the doctor for advice.</li><li>if you have a localised reaction at the injection site or generalised allergic reaction with INCRELEX. Call the doctor as soon as possible if you get a localised rash. Get medical help immediately if you have a generalised allergic reaction (hives, trouble breathing, faintness or collapse and feeling generally unwell).</li><li>if you have finished growing (the bone growth plates are closed). In this case INCRELEX cannot help you grow and should not be used.</li></ul><p>Children under 2 years old</p><p>The use of this medicine has not been studied in children under 2 years of age and is therefore not recommended.</p><p>Other medicines and INCRELEX</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Especially tell the doctor if you take insulin or other anti-diabetes medicines. A dose adjustment may be needed for these medicines.</p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p>A negative pregnancy test is recommended for all women of child bearing potential prior to treatment with mecasermin. It is also recommended that all women of childbearing potential use adequate contraception during treatment.</p><p>Mecasermin therapy should be discontinued if pregnancy occurs.</p><p>Mecasermin should not be administered to a breast-feeding mother.</p><p>Driving and using machines</p><p>Mecasermin may cause hypoglycaemia (very common side effect, see section 4) that may impair your ability to drive and use machines because your ability to concentrate or react may be reduced.</p><p>You should avoid engaging in any high-risk activities (e.g., driving, etc.) within 2-3 hours after dosing, particularly at the start of INCRELEX treatment, until a dose of INCRELEX has been found which does not cause side effects that make these activities risky.</p><p>INCRELEX contains benzyl alcohol and sodium</p><p>INCRELEX contains benzyl alcohol as a preservative which may cause toxic reactions and allergic reactions in infants and children up to 3 years old.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially sodium- free .</p></div>"
}
},
{
"title" : "3. How to take increlex",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take increlex"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The typical dose is 0.04 to 0.12 mg/kg of patient weight administered twice a day. See the Instructions for Use at the end of this leaflet.</p><p>Inject INCRELEX just under your skin shortly before or after a meal or snack because it may have insulin-like hypoglycaemic effects and so it may decrease blood sugar levels (see hypoglycaemia in section 4). Do not inject your dose of INCRELEX if you cannot eat for any reason. Do not make up the missed dose by giving two doses the next time. The next dose should be taken as usual, with a meal or snack.</p><p>Inject INCRELEX just below the skin in your upper arm, upper leg (thigh), stomach area (abdomen), or buttocks. Change the injection site for each injection. Never inject it into a vein or muscle.</p><p>Only use INCRELEX that is clear and colourless.</p><p>Treatment with mecasermin is a long-term therapy. For further information ask the doctor.</p><p>If you use more INCRELEX than you should</p><p>Mecasermin, like insulin, may lower blood sugar levels (see hypoglycaemia in section 4).</p><p>If more INCRELEX than recommended was injected, contact your doctor immediately.</p><p>Acute overdose could lead to hypoglycaemia (low blood sugar).</p><p>Treatment of acute overdose of mecasermin should be directed at reversing hypoglycaemia. Sugar- containing fluids or food should be consumed. If the patient is not awake or alert enough to drink sugar-containing fluids, an injection of glucagon into the muscle may be necessary to reverse the low blood sugar. Your doctor or nurse will instruct you how to give the injection of glucagon.</p><p>Long-term overdose may result in enlargement of certain body parts (e.g., hands, feet, parts of the face) or excessive growth of the whole body. If you suspect long-term overdose, contact your doctor immediately.</p><p>If you forget to use INCRELEX</p><p>Do not use a double dose to make up for a forgotten dose. If a dose is skipped, the next dose should not be made larger to compensate. The next dose should be taken as usual, with a meal or snack.</p><p>If you stop using INCRELEX</p><p>A disruption or early ending of treatment with mecasermin may impair the success of the growth therapy. Please ask the doctor for advice before stopping the treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>The most frequently occurring side effects with mecasermin are: low blood sugar (hypoglycemia), vomiting, injection site reactions, headache and middle ear infections. Serious allergic reactions have also been reported with INCRELEX. If you develop any of these events, please follow the advice given for each event in the sections below.</p><p>Frequency not known (frequency cannot be estimated from the available data) Cancerous and non-cancerous tumours An increase in both cancerous and non-cancerous tumours has been reported in patients treated with INCRELEX. The risk of such tumours may be higher if INCRELEX is used for condition other than what is stated in Section 1 or used at higher than recommended dose as per Section 3. Serious allergic reactions (anaphylaxis) Generalised hives, difficulty in breathing, dizziness, swelling of the face and/or throat have been reported following mecasermin use. Stop INCRELEX immediately and seek urgent medical advice if you develop a serious allergic reaction. Local allergic reactions at the injection site (itching, hives) have also been reported.</p><p>Hair loss (alopecia) Hair loss has also been reported following mecasermin use.</p><p>Very common (may affect more than 1 in 10 people) Low blood sugar (hypoglycaemia)<br/>Mecasermin may lower blood sugar levels. Signs of low blood sugar are: dizziness, tiredness, restlessness, hunger, irritability, trouble concentrating, sweating, nausea and fast or irregular heartbeats.</p><p>Severe hypoglycaemia may cause unconsciousness, seizures/fits or death. Stop INCRELEX immediately and seek urgent medical advice if you develop seizures/fits or become unconscious.</p><p>If you take INCRELEX, you should avoid participating in high risk activities (such as vigorous physical activity) within 2 to 3 hours after INCRELEX injection, especially at the beginning of INCRELEX treatment.</p><p>Before beginning treatment with INCRELEX the doctor or nurse will explain to you how to treat hypoglycaemia. You should always have a source of sugar such as orange juice, glucose gel, sweets, or milk available in case symptoms of hypoglycaemia occur. For severe hypoglycaemia, if you are not responsive and cannot drink sugar-containing fluids, you should give an injection of glucagon. The doctor or nurse will instruct you how to give the injection. Glucagon raises the blood sugar when it is injected. It is important that you have a well-balanced diet including protein and fat such as meat and cheese in addition to sugar-containing foods.</p><p>You should be monitored at fingertip for blood sugar (glucose) before each meal at treatment initiation and until a well-tolerated dose is established. If frequent symptoms of hypoglycaemia or severe hypoglycaemia occur, blood sugar monitoring should continue regardless of eating condition and if possible, in case of hypoglycaemic symptoms.</p><p>Injection site hypertrophy (tissue at injection site increases in size) and bruising These can be avoided by changing the injection site at each injection (injection site rotation).</p><p>Digestive system<br/>Vomiting and pain in the upper belly have occurred with mecasermin treatment.</p><p>Infections Infections of the middle ear have been observed in children with mecasermin treatment.</p><p>Musculoskeletal system Joint pains and pains in the limbs have occurred with mecasermin treatment.</p><p>Nervous system Headache has occurred with mecasermin treatment.</p><p>Common (may affect up to 1 in 10 people) Seizures Seizures (fits) have been observed with mecasermin treatment. Dizziness and tremor have also been reported with mecasermin treatment.</p><p>Heart abnormalities<br/>A fast heart rate and abnormal heart sounds have been reported with mecasermin treatment.</p><p>Increased blood sugar (hyperglycaemia) Increased blood sugar has also been observed with mecasermin treatment.</p><p>Enlarged tonsils/adenoids Mecasermin may enlarge your tonsils/adenoids. Some signs of enlarged tonsils/adenoids include: snoring, difficulty breathing or swallowing, sleep apnoea (a condition where breathing stops briefly during sleep), or fluid in the middle ear, as well as infections of the ear. Sleep apnea can cause excessive daytime sleepiness. Call the doctor should these symptoms bother you. The doctor should regularly examine your tonsils/adenoids.</p><p>Enlarged thymus An enlarged thymus (a specialized organ of the immune system) has been observed with mecasermin treatment.</p><p>Papilloedema A swelling at the back of the eye (due to increased pressure within the brain) may be observed by a doctor or optician during mecasermin treatment.</p><p>Hypoacusis (hearing loss) Hypoacusis (hearing loss), ear pain and fluid in the middle ear have been observed with mecasermin treatment. Tell the doctor if you develop hearing problems.</p><p>Worsened scoliosis (caused by rapid growth) If you have scoliosis, you will need to be checked often for an increase in the curve of the spine.<br/>Pain in muscles has also been seen with mecasermin treatment.</p><p>Reproductive system Breast enlargement has been observed with mecasermin treatment.</p><p>Digestive system<br/>Pain in the belly has occurred with mecasermin treatment.</p><p>Skin and hair changes Skin thickening, moles and abnormal hair texture have been seen with mecasermin treatment.</p><p>Reactions at the injection site Reactions including pain, irritation, bleeding, bruising, redness and hardening have been reported with INCRELEX treatment. Injection site reactions can be avoided by changing the injection site at each injection (injection site rotation).</p><p>Uncommon (may affect up to 1 in 100 people)<br/>Increased pressure in the brain (intracranial hypertension) INCRELEX can sometimes cause a temporary increase in pressure within the brain. The symptoms of intracranial hypertension can include visual changes, headache, nausea and/or vomiting. Tell the doctor immediately if you have any of these symptoms. Your doctor can check to see if intracranial hypertension is present. If it is present, your doctor may decide to temporarily reduce or discontinue mecasermin therapy. Mecasermin may be started again after the episode is over.</p><p>Heart abnormalities In some patients treated with mecasermin, an ultrasound examination of the heart (echocardiogram) showed an increased size of the heart muscle and abnormalities of heart valve function. Your doctor may perform an echocardiogram before, during and after mecasermin treatment.</p><p>Reactions at the injection site Reactions including rash, swelling and fatty lumps have been reported with INCRELEX treatment. Injection site reactions can be avoided by changing the injection site at each injection (injection site rotation).</p><p>Weight increase Weight increase has been observed with mecasermin treatment.</p><p>Other uncommon side effects seen with mecasermin treatment include depression, nervousness.</p><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store increlex",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store increlex"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of the month.</p><p>Store in a refrigerator (2 C - 8 C). Do not freeze.<br/>Keep the vial in the outer carton in order to protect from light.<br/>After first use, the vial may be stored for up to 30 days at 2 C to 8 C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What INCRELEX contains</p><ul><li>The active substance is mecasermin. One ml contains 10 mg of mecasermin. Each vial contains 40 mg of mecasermin.</li><li>The other ingredients are: benzyl alcohol, sodium chloride, polysorbate 20, glacial acetic acid, sodium acetate and water for injections (see section 2 \"INCRELEX contains benzyl alcohol and sodium\").</li></ul><p>What INCRELEX looks like and contents of the pack</p><p>INCRELEX is a colourless to slightly yellow and clear to slightly opalescent solution for injection (injection) supplied in a glass vial closed with a stopper and a seal. The vial contains 4 ml of solution.</p><p>Pack size of 1 vial.</p><p>Marketing Authorisation Holder and Manufacturer</p><p>Marketing Authorisation Holder: Ipsen Pharma 65, quai Georges Gorse 92100 Boulogne-Billancourt<br/>France</p><p>Manufacturer: Beaufour Ipsen Industrie Rue Eth Virton 28100 Dreux France</p><p>Tjoapack Netherlands B.V.<br/>Nieuwe Donk 9<br/>4879 AC Etten-Leur<br/>The Netherlands</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien,<br/>Luxembourg/Luxemburg Ipsen NV Belgi /Belgique/Belgien<br/>T l/Tel: + 32 9 243 96 Italia Ipsen SpA Tel: + 39 02 39 22<br/>Biomapas UAB Tel: +370 37 366Latvija Ipsen Pharma p rst vniec ba Latvij<br/>Tel: +371 67622 esk republika Ipsen Pharma, s.r.o. Tel: + 420 242 481 Hrvatska<br/>Biomapas Zagreb d.o.o.,<br/>Tel: +385 17 757 Lietuva Ipsen Pharma Lietuvos filialas Lietuva Tel. + 370 37 337Danmark, Norge, Suomi/Finland, Sverige, sland Institut Produits Synth se (IPSEN) AB Sverige/Ruotsi/Sv j<br/>Tlf/Puh/Tel/S mi: +46 8 451 60 Magyarorsz g Ipsen Pharma SAS Magyarorsz gi<br/>Tel.: + 36 1 555 5Deutschland, sterreich Ipsen Pharma GmbH Deutschland Tel.: +49 89 262043Nederland Ipsen Farmaceutica B.V. Tel: + 31 23 55 41 Eesti Centralpharma Communications O<br/>Tel: +372 6015Polska Ipsen Poland Sp. z o.o. Tel.: + 48 (0) 22 653 68 , , Malta Ipsen E</p><p>: + 30 210 984 3Portugal Ipsen Portugal - Produtos Farmac uticos S.A. Tel: + 351 21 412 3Espa a Ipsen Pharma S.A. Tel: + 34 936 858 Slovenija Biomapas UAB Tel: +370 37 366France Ipsen Pharma T l: + 33 1 58 33 50 Slovensk republika Ipsen Pharma, organiza n zlo ka<br/>Tel: + 420 242 481 Ireland, United Kingdom (Northern Ireland) Ipsen Pharmaceuticals Limited Ireland Tel: + 44(0)1753 627Rom nia Ipsen Pharma Rom nia Tel/ .: + 40 (021) 231 27 This leaflet was last revised in</p><p>This medicine has been authorised under exceptional circumstances . This means that because of the rarity of this disease it has been impossible to get complete information on this medicine. The European Medicines Agency will review any new information on this medicine every year and this leaflet will be updated as necessary.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp56dfb582fe4596bebf9f4c8e3931299d",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp56dfb582fe4596bebf9f4c8e3931299d",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp56dfb582fe4596bebf9f4c8e3931299d\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp56dfb582fe4596bebf9f4c8e3931299d</b></p><a name=\"mp56dfb582fe4596bebf9f4c8e3931299d\"> </a><a name=\"hcmp56dfb582fe4596bebf9f4c8e3931299d\"> </a><a name=\"mp56dfb582fe4596bebf9f4c8e3931299d-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/402/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: INCRELEX 10 mg/ml solution for injection</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/07/402/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "INCRELEX 10 mg/ml solution for injection",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
